Drug Profile


Alternative Names: LFG-316; NOV-4

Latest Information Update: 10 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MorphoSys; Novartis
  • Class Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Complement C5 inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Choroiditis; Dry age-related macular degeneration; Panuveitis; Paroxysmal nocturnal haemoglobinuria; Thrombotic microangiopathy; Wet age-related macular degeneration

Most Recent Events

  • 28 Sep 2017 Novartis terminates a phase II trial in Thrombotic microangiopathy (In adolescents, In children, In adults) in United Kingdom, Germany, France, USA (IV) (EudraCT2014-004972-49) (NCT02763644)
  • 24 Aug 2017 Novartis completes a phase II trial for Multifocal choroiditis & Panuveitis in United Kingdom and USA (Intravitreous) (NCT01526889)
  • 19 Jul 2017 Novartis Pharmaceuticals completes a drug-drug interaction phase I trial in USA (unspecified route) (NCT02878616)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top